Cancer immunotherapy drugs, including CTLA‐4, PD‐1 and PD‐L1 inhibitors, induce the reactivation of T cells for immune response to the tumor effect, thereby achieving an antitumor role.10 The gene discussed is CD274; the disease is neoplasm.